gatifloxacin has been researched along with sitafloxacin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Sano, C; Sato, K; Shimizu, T; Tomioka, H | 2 |
| Cai, S; Kamei, T; Ogasawara, K; Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Chiba, K; Hagiwara, T; Hashimoto, K; Sugiyama, A; Takahashi, S; Takasuna, K | 1 |
| Chen, XY; Doi, N; Duan, HF; Fu, Y; Li, Q; Ma, Y | 1 |
| Sano, C; Sato, K; Shimizu, T; Tatano, Y; Tomioka, H; Yamabe, S | 1 |
13 other study(ies) available for gatifloxacin and sitafloxacin
| Article | Year |
|---|---|
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
Topics: Anti-Infective Agents; Cell Line; Clarithromycin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex | 2002 |
Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Cell Line; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2002 |
Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Cell Line; Epithelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Macrophages; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli | 2003 |
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Dogs; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Halothane; Heart Block; Heart Rate; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left | 2004 |
[Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents].
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2010 |
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2011 |